ストックスクリーナーアプリを入手
1.12
154.49%
0.6799
プレマーケット:
1.07
-0.05
-4.46%
前日終値:
$0.4401
開ける：
$1.3
24時間の取引高:
288.74M
Relative Volume:
48.29
時価総額：
$36.61M
収益：
-
当期純損益:
$-563.30K
株価収益率:
-5.6112
EPS:
-0.1996
ネットキャッシュフロー:
$-22.23M
1週間 パフォーマンス:
+115.38%
1か月 パフォーマンス:
+124.00%
6か月 パフォーマンス:
+13.25%
1年 パフォーマンス:
-46.46%
1日の値動き範囲:
$0.91
$1.59
1週間の範囲:
$0.40
$1.59
52週間の値動き範囲:
$0.38
$2.20
Promis Neurosciences Inc Stock (PMN) Company Profile
名前
Promis Neurosciences Inc
セクター
電話
416-847-6898
住所
SUITE 200, 1920 YONGE STREET, TORONTO
PMN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
1.12 | 17.00M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Promis Neurosciences Inc (PMN) 最新ニュース
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules - The Manila Times
ProMIS Neurosciences Announces Private Placement Financing | PMN Stock News - GuruFocus
ProMIS Neurosciences Gains FDA Fast Track for PMN310 - TipRanks
ProMIS Neurosciences Announces Private Placement Financing - GlobeNewswire
ProMIS Secures $9.2M Funding Boost: Accelerates Novel Alzheimer's Treatment Development - Stock Titan
ProMIS Neurosciences ends at-the-market agreement and receives FDA fast track for PMN310 - Investing.com Australia
What drives ProMIS Neurosciences Inc. stock priceRapid portfolio appreciation - Autocar Professional
ProMIS Neurosciences Inc Inc. (PMN) Price Performance: The Role of Supply and Demand - investchronicle.com
ProMIS Neurosciences shares surge 149.77% intraday after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
Shares Of Micro Cap Biotech Surge After Breakthrough FDA Designation - The Globe and Mail
Alzheimer’s stock triples after FDA Fast-Track Designation | 2025-07-21 | Investing News - Stockhouse
ProMIS Neurosciences Soars 134%—What’s Fueling This Biotech Breakout? - AInvest
ProMIS Neurosciences (PMN) up more than 300% since Jul 8 - AInvest
Promis Neurosciences shares surge 250% intraday after FDA grants Fast Track designation for PMN310 Alzheimer's treatment. - AInvest
ProMIS Neurosciences: Stock Surge Insight - StocksToTrade
ProMIS Neurosciences Soars 131% on FDA Fast Track Designation – What’s Next for PMN? - AInvest
ProMIS Neurosciences shares surge 21.37% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
ProMIS Neurosciences stock price surges in pre market trading as company receives FDA fast track designation for alzheimer’s drug candidate PMN310 - MSN
Why Is ProMIS Neurosciences Stock (PMN) Up 180% Today? - TipRanks
ProMIS Neurosciences shares surge 17.50% premarket after FDA grants Fast Track designation to PMN310 for Alzheimer’s treatment. - AInvest
ProMIS Neurosciences stock soars after FDA grants Fast Track for Alzheimer’s drug - Investing.com India
Why ProMIS Is Rising In Pre-market? - Nasdaq
FDA grants fast track designation to ProMIS Neurosciences’ Alzheimer’s drug By Investing.com - Investing.com South Africa
FDA grants fast track designation to ProMIS Neurosciences’ Alzheimer’s drug - Investing.com Australia
ProMIS Neurosciences granted Fast Track designation by FDA for PMN310 - TipRanks
ProMIS Neurosciences Granted Fast Track Designation by U.S. - GlobeNewswire
FDA Fast-Tracks Revolutionary Alzheimer's Drug Promising Fewer Side Effects Than Current Treatments - Stock Titan
What analysts say about ProMIS Neurosciences Inc. stockRapid return acceleration - PrintWeekIndia
ProMIS Neurosciences Inc. Stock Analysis and ForecastSuperior stock selection - PrintWeekIndia
Is ProMIS Neurosciences Inc. a good long term investmentSuperior profit margins - jammulinksnews.com
Q2 Earnings Forecast for PMN Issued By HC Wainwright - Defense World
HC Wainwright Initiates Coverage on Promis Neurosciences (NASDAQ:PMN) - Defense World
What makes ProMIS Neurosciences Inc. stock price move sharplyLong Term Safe Yield Focus - Newser
Why ProMIS Neurosciences Inc. stock attracts strong analyst attentionTop Gaining Low Risk Assets - Newser
How ProMIS Neurosciences Inc. stock performs during market volatilityFree High-Accuracy Stock Picks - Newser
ProMIS Neurosciences Receives "Buy" Rating from HC Wainwright & Co. - AInvest
H.C. Wainwright Initiates ProMIS Neurosciences with Buy Rating, $4 Price Target - AInvest
ProMIS Neurosciences Insiders Still US$234k Away From Original Investment Value - simplywall.st
Why Community Healthcare Trust Incorporated stock attracts strong analyst attentionCapital Protected Stock Selections - Newser
Why Labcorp Holdings Inc. stock attracts strong analyst attentionHigh Reward Swing Trades - Newser
ProMIS Neurosciences Plunges 12.12% Amid Clinical Trial Uncertainty - AInvest
Promis Neurosciences Inc (PMN) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
0.17%
大文字化:
|
ボリューム (24 時間):